ilikefinance

Vivos Therapeutics Successfully Closes $4 Million Private Placement

Vivos Therapeutics Closes $4 Million Private Placement Littleton, Colo., Nov. 02, 2023 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS) Vivos Therapeutics, a medical technology company specializing in developing innovative treatments for patients with dentofacial abnormalities, mild-to-moderate obstructive sleep apnea (OSA), and snoring in adults, has announced the successful closure of…

Read More

Attention Investors: Abbott Cooper PLLC Launches Investigation into Medifast Inc. – Take Action Now!

Investor Alert: Abbott Cooper PLLC Investigates Medifast, Inc. Stamford, Conn., Nov. 02, 2023 (GLOBE NEWSWIRE) Abbott Cooper PLLC is investigating Medifast, Inc. (NYSE: MED) (“Medifast” or the “Company”) on behalf of the Company’s investors. The investigation seeks to determine whether Medifast’s board of directors (the “Board”) has violated its fiduciary duty by instituting measures intended…

Read More

Attention Investors: Abbott Cooper PLLC Launches Investigation into Sight Sciences Inc. – Take Action Now to Protect Your Legal Rights!

Investor Alert: Abbott Cooper PLLC Investigates Sight Sciences, Inc. STAMFORD, Conn., Nov. 02, 2023 (GLOBE NEWSWIRE) — Abbott Cooper PLLC is currently investigating Sight Sciences, Inc. (Nasdaq: SGHT) on behalf of the Company’s investors. This investigation is aimed at determining whether the board of directors at Sight Sciences has breached their fiduciary duty by implementing…

Read More

Attention Investors: Don’t Let Your Losses Tandem with Tandem Diabetes Care Inc. – Contact The Portnoy Law Firm Now!

Investors Urged to Seek Legal Assistance Following Tandem Diabetes Care Lawsuit LOS ANGELES, Nov. 01, 2023 (GLOBE NEWSWIRE) — The Portnoy Law Firm has recently advised Tandem Diabetes Care, Inc. investors about a lawsuit filed on behalf of individuals who purchased Tandem securities during a specified period. The lawsuit aims to help investors recover potential…

Read More

Unlocking the Power of ITK Inhibition: Corvus Pharmaceuticals’ Groundbreaking Research on Soquelitinib for T-Cell Inflammatory and Immune Diseases

Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of Soquelitinib Data demonstrated soquelitinib was active in six inflammatory/immune disease models and provides rationale for development in a range of additional Th2- and Th17-mediated diseases Corvus Pharmaceuticals has recently announced the publication of preclinical data showcasing the promising potential of their drug, Soquelitinib. The data…

Read More